Value of procollagen type 1 amino-terminal propeptide in patients with renal cell carcinoma

Anticancer Research

Volumn 28, Issue 4 C, 2008, Pages 2443-2446

  Klepzig, M ^a   Sauer Eppel, H ^a   Jonas, D ^a   Oremek, G M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

AP; Bone metastases; P1NP; Renal cell carcinoma; Tumour marker

Indexed keywords

COLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; SORAFENIB; TUMOR MARKER;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOASSAY; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGED; BONE NEOPLASMS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROCOLLAGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 48849108944     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. American Cancer Society: Cancer Facts and Figures 2007. American Cancer Society, Atlanta, 2007.
2. Lipton A, Colombo-Berra A, Bukowski A, Rosen L, Zheng M and Urbanowitz G: Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10: 6397-6403, 2004.
3. Staudenherz A, Steiner B, Puig S, Kainberger F and Leitha T: Is there a diagnostic role for bone scanning of patients with a high pretest probability for metastatic renal cell carcinoma? Cancer 85: 153-155, 1999.
4. Seibel MJ: Biochemical markers of bone turnover part I: biochemistry and variability. Clin Biochem Rev 26: 97-122, 2005.
5. Castro-Errecaborde NA, Traba LM, Méndez-Dávila C, Garcia-Moreno C, Rodriguez de Acuna L and Rodriguez-Molina J: Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin Chim Acta 331: 45-53, 2003.
6. Koizumi M, Yonese J, Fukui I and Ogata E: The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone. BJU Int 87: 348-351, 2001.
7. Tähtelä R and Thölix E: Serum concentration of type I collagen carboxyterminal propeptide and type I procollagen carboxy - and aminoterminal propeptides as markers of metastatic bone disease in breast cancer. Anticancer Res 16: 2289-2294, 1996.
8. Jung K, Lein M, Ringsdorf M, Roigas J, Schnorr D, Loening SA and Staack A: Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol 176: 1326-1331, 2006.
9. Seibel MJ: Biochemical markers of bone remodeling. Endocr Metab Clin N Am 32: 83-113, 2003.
10. Rasch-Isla Muñoz A and Cataño Cataño JG: Usefulness of bone-specific alkaline phosphatase for bone metastases detection in prostate cancer. Arch Españ Urol 57: 693-698, 2004.
11. Kriteman L and Sanders WH: Normal alkaline phosphatase levels in patients with bone metastases due to renal cell carcinoma. Urology 51: 397-399, 1998.
12. Escudier B, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA and Rolland F: Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356: 125-134, 2007.
13. Ryan CW, Goldman BH, Lara PN, Mack PC, Beer TM, Tangen CM, Lemmon D, Pan C-X, Drabkin HA and Crawford ED: Sorafenib with Interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol 25: 3296-3301, 2007.
14. Bracarda S, Caserta C, Sordini L, Rossi M, Hamzay A and Crino L: Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Ann Oncol 18(Suppl 6): vi22-vi25, 2007.
15. Cohen HT and McGovern FJ: Renal-cell carcinoma. New Eng J Med 353: 2477-2490, 2005.
16. Sciarra A, Gomez AM, Gentilucci A, Parente U, Salciccia S, Gentile V and Di Silverio F: Adjuvant therapy with sorafenib in bone metastases - bilateral renal carcinoma: a case report. Eur Urol 52: 597-599, 2007.